This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

General contraindications to the progesterone only contraceptive pill

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Criteria for Exclusion of POP:

  • Consent not given.
  • Individuals under 16 years of age and assessed as not competent using Fraser Guidelines.
  • Individuals 16 years of age and over and assessed as lacking capacity to consent.
  • Known or suspected pregnancy.
  • Known hypersensitivity to the active ingredient or to any constituent of the product - see Summary of Product Characteristics
  • Individuals using enzyme-inducing drugs/herbal products or within 4 weeks of stopping them.
  • Acute porphyria

Cardiovascular Disease

  • Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic first attack only if taking the method when the event occurred.

Cancers

  • Current or past history of breast cancer.
  • Benign liver tumour (hepatocellular adenoma).
  • Malignant liver tumour (hepatocellular carcinoma).

Gastro-intestinal conditions

  • Severe decompensated cirrhosis.
  • Any bariatric or other surgery resulting in malabsorption.

Interacting medicines (other than enzyme inducers) –-see current British National Formulary (BNF) www.bnf.orgor individual product SPC http://www.medicines.org.uk

Reference:

  • Patient Group Direction (PGD) (NHS Specialist Pharmacy Service). Supply of a progestogen only contraceptive pill (POP) . (Accessed 18th March 2021).

 

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.